Laboratories seeking to purchase GHRP-2 require high-purity research-grade reagents supported by comprehensive analytical verification. GHRP-2 (Growth Hormone Releasing Peptide-2) is a synthetic hexapeptide growth hormone secretagogue widely studied in preclinical settings for its selective binding affinity to the ghrelin receptor (GHS-R1a) and its activation of pituitary somatotrophs. PX1 Research supplies USA-manufactured GHRP-2 with lot-specific, third-party Certificates of Analysis (COA) detailing RP-HPLC purity, mass spectrometry confirmation, and endotoxin screening for in vitro and animal research models.
Laboratories seeking to purchase GHRP-2 require high-purity research-grade reagents supported by comprehensive analytical verification. GHRP-2 (Growth Hormone Releasing Peptide-2) is a synthetic hexapeptide growth hormone secretagogue widely studied in preclinical settings for its selective binding affinity to the ghrelin receptor (GHS-R1a) and its activation of pituitary somatotrophs. PX1 Research supplies USA-manufactured GHRP-2 with lot-specific, third-party Certificates of Analysis (COA) detailing RP-HPLC purity, mass spectrometry confirmation, and endotoxin screening for in vitro and animal research models.
GHRP-2 (D-Ala-D-2-Nal-Ala-Trp-D-Phe-Lys-NH2) is a second-generation synthetic growth hormone secretagogue (GHS) belonging to the hexapeptide class. Originally synthesized to improve upon early non-natural peptide secretagogues, GHRP-2 operates as a potent agonist at the growth hormone secretagogue receptor 1a (GHS-R1a), a G-protein coupled receptor predominantly localized within the anterior pituitary gland and hypothalamic nuclei.
In preclinical laboratory investigations, researchers utilize GHRP-2 to explore signaling cascades governing endogenous growth hormone (GH) secretion. Unlike growth hormone-releasing hormone (GHRH), which signals via the GHRH receptor and cAMP-dependent pathways, GHRP-2 initiates intracellular calcium influx through phospholipase C (PLC) activation. This distinction makes it an important reference compound in comparative neuroendocrine assays across various research peptides targeting pituitary somatotroph regulation.
Preclinical studies evaluate GHRP-2 primarily for its targeted secretagogue activity and receptor kinetics. In vitro assays using primary rat pituitary cell cultures demonstrate that GHRP-2 induces dose-dependent growth hormone release at nanomolar concentrations, demonstrating higher potency compared to first-generation hexapeptides.
In animal models, investigators have examined GHRP-2's capacity to stimulate pulsatile GH release, influence food intake behaviors, and alter substrate metabolism. Rodent studies indicate that GHRP-2 activation of GHS-R1a in central hypothalamic circuits leads to transient increases in food intake mediated by orexigenic neuropeptide Y (NPY) neurons. Additional preclinical investigations explore the peptide's effects on cardiac tissue preservation, inflammatory marker modulation, and nitrogen retention in catabolic animal models.
When evaluating growth hormone secretagogues for comparative receptor binding assays, research teams frequently analyze structural and functional variations across the GHRP family. GHRP-2, GHRP-6, Ipamorelin, and Hexarelin share the common core objective of GHS-R1a activation, yet exhibit distinct pharmacological profiles in preclinical literature.
While GHRP-6 exhibits significant appetite-stimulating activity in rodent models due to robust hypothalamic NPY recruitment, GHRP-2 demonstrates greater relative potency in GH release per mass unit with moderate orexigenic stimulation. In contrast, Ipamorelin is recognized for its high receptor selectivity, failing to induce significant elevations in cortisol or prolactin levels in animal models, whereas Hexarelin displays the highest immediate secretagogue potency alongside cardiac receptor interaction capabilities. Researchers selecting among these compounds often evaluate specific signaling downstream pathways in our comprehensive catalog of all peptides.
When planning to purchase GHRP-2 for analytical or cell-culture protocols, verifying chemical identity and purity is essential to ensure reproducible experimental outcomes. Impurities such as truncated peptide sequences, organic solvent residues, or counterion imbalances can confound bioassay results and introduce extraneous variables.
PX1 Research enforces strict quality assurance protocols for every lot of GHRP-2 synthesized. Each batch undergoes rigorous testing in an ISO 17025 accredited laboratory facility utilizing Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) to confirm high chemical purity (typically >98%) and Matrix-Assisted Laser Desorption/Ionization (MALDI-TOF) or Liquid Chromatography-Mass Spectrometry (LC-MS) to confirm precise molecular mass.
For cell culture research and sensitive in vivo rodent assays, endotoxin contamination presents a significant risk of non-specific inflammatory responses. Bacterial lipopolysaccharides (LPS) present in poorly refined peptide preparations can skew cytokine profiles, alter gene expression, and cause severe systemic interference.
To prevent experimental artifacts, PX1 Research evaluates all research peptides for bacterial endotoxin content using standardized Chromogenic Recombinant Factor C (rFC) or Limulus Amebocyte Lysate (LAL) assays. Our lot-specific COAs confirm endotoxin levels well below maximum acceptable research thresholds, ensuring safe integration into delicate laboratory models.
Proper reconstitution techniques are crucial to maintaining peptide integrity and avoiding aggregation or catalytic degradation. Lyophilized GHRP-2 should be equilibrated to room temperature inside a desiccated cabinet prior to opening the vial to prevent atmospheric moisture condensation on the cake.
Reconstitution should be conducted using sterile laboratory-grade diluents such as Bacteriostatic Water (0.9% benzyl alcohol), Sterile Water for Injection, or specialized assay buffers (e.g., PBS at neutral pH) depending on experimental requirements. Gentle swirl movement is recommended to achieve total dissolution; mechanical agitation or vortexing must be avoided to prevent surface-induced aggregation of peptide chains.
Lyophilized GHRP-2 supplied by PX1 Research demonstrates high chemical stability when stored under appropriate environmental controls. Unreconstituted vials should be stored at -20°C for short-to-medium term storage, or at -80°C for long-term preservation, protected from direct light exposure.
Once reconstituted into aqueous solution, peptide stability decreases over time due to potential hydrolysis or oxidation. Reconstituted stock solutions should be divided into single-use aliquots using low-binding polypropylene tubes to avoid repeated freeze-thaw cycles. Liquid aliquots stored at 2°C to 8°C should be utilized within recommended short-term experimental windows, or frozen at -20°C or colder for extended protocol execution.
Sourcing peptides from reliable domestic suppliers reduces supply chain vulnerabilities, customs clearance delays, and lot-to-lot purity variances. PX1 Research synthesizes and packages GHRP-2 in modern, GMP-compliant facilities within the United States, operating fulfillment centers in California and Arizona.
By maintaining strict control over manufacturing parameters, storage conditions, and swift dispatch protocols, PX1 Research guarantees that investigators receive pristine, stable reagents. Institutional buyers, academic laboratories, and principal investigators requiring large-scale allocations or routine procurement schedules can coordinate customized orders via our dedicated wholesale account management portal.
What is the certified purity level of GHRP-2 from PX1 Research?
PX1 Research provides GHRP-2 with a verified minimum purity of 98%, confirmed via Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) and mass spectrometry analysis detailed on every lot-specific COA.
How is GHRP-2 verified for identity and structural integrity?
Structural identity is verified using Liquid Chromatography-Mass Spectrometry (LC-MS) or MALDI-TOF mass spectrometry to confirm exact molecular weight match against theoretical sequences prior to lot release.
Are endotoxin levels documented for every batch of GHRP-2?
Yes. Every lot of GHRP-2 undergoes analytical endotoxin testing via LAL or rFC assays, ensuring endotoxin levels remain below standard lab threshold limits suitable for sensitive in vitro and in vivo models.
How should reconstituted GHRP-2 stock solutions be stored?
Reconstituted GHRP-2 should be divided into single-use aliquots using low-protein-binding microcentrifuge tubes and stored at -20°C or -80°C to prevent hydrolysis and avoid degradation from repeated freeze-thaw cycles.
What receptor target is primarily investigated when researching GHRP-2?
GHRP-2 acts primarily as an agonist at the Growth Hormone Secretagogue Receptor 1a (GHS-R1a), a G-protein coupled receptor involved in pituitary somatotroph signaling and hypothalamic ghrelin axis activation.
How does GHRP-2 differ from Ipamorelin in preclinical models?
In preclinical studies, GHRP-2 exhibits greater growth hormone releasing potency per mass unit but can cause modest increases in secondary hormones like prolactin and ACTH, whereas Ipamorelin demonstrates extreme selectivity for GH release without elevating secondary pituitary hormones.
Where does PX1 Research ship GHRP-2 orders from?
PX1 Research synthesizes and warehouses research compounds within USA-based GMP-compliant facilities and fulfills orders directly from dispatch centers in California and Arizona with same-day shipping options.
Can institution researchers set up bulk procurement for GHRP-2?
Yes, university laboratories, contract research organizations (CROs), and institutional researchers can submit bulk reagent inquiries directly through the PX1 Research wholesale program.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.